Marvel Biosciences Corp. awarded 50,001 deferred share units (DSUs) to its three independent directors as payment for their fees, replacing cash payments. These DSUs will vest on May 19, 2027, and will be settled when the directors leave the company. The value of the DSUs is based on the company's share price of $0.15 as of May 19, 2026. Marvel Biosciences is developing a new drug candidate, MB-204, targeting neurological diseases, with potential applications beyond Parkinson's, including autism and Alzheimer's disease.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
